MDR Gram-negative Infections

This site is intended only for healthcare professionals residing in Singapore

Log Out

Our medicines

Therapy areas

Explore content

Events

Materials

Videos

Let’s connect

Medical Information

Think Fungus, Save Lives

MDR Gram-negative Infections

CAP and cSSTI Infections

Understand the Gram Negatives

Pfizer has a long-standing commitment to tackling antimicrobial resistance (AMR), as well as a willingness to collaborate with antimicrobial stewardship committees and other stakeholders. One focus is on MDR Gram-negative infections which present serious clinical challenges.

Gram-negative Bacteria

Carbapenem-resistant Enterobacterales (CRE) (in particular Metallo-β-lactamases, Klebsiella pneumoniae carbapenemases, and oxacillinase-type carbapenemases), carbapenem-resistant Pseudomonas aeruginosa (CRPA), carbapenem-resistant Acinetobacter baumannii (CRAB), and third-generation cephalosporin-resistant Gram-negative bacteria are resistant to numerous existing treatment options.¹ Gram-negative bacteria exhibiting resistance to all fluoroquinolones and all β-lactam categories, including carbapenems, are known as ‘difficult-to-treat’. ¹

Dealing with Antimicrobial Resistance (AMR)

Antimicrobial resistance (AMR) is a growing threat, especially among Gram-negative bacteria. Emergence of resistance to β-lactam antibiotics - the most potent and prescribed class of antibiotic - is mainly due to the production of β-lactamase enzymes. Metallo-β-lactamase (MBL) enzymes are a particular concern and increasingly disseminated worldwide.^2,3

Understanding MBLs

Find out more about the growing threat of antimicrobial resistance caused by MBL-producing Gram-negative bacteria.

Learn more

Dispel the CRE

Explore clinical evidence and resources to help healthcare professionals in the management of patients at high risk of multidrug resistant Gram-negative infections.

Learn more

Abbreviations:

MDR, multidrug resistant.

Bassetti M et al. JAC Antimicrob Resist 2022;4(5):dlac089.

Boyd SE et al. Antimicrob Agents Chemother 2020;64(10):e00397-20.

Mojica MF et al. Lancet Infect Dis 2022;22(1):e28–e34.

PP-UNP-SGP-0302/01APR2026

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Account

Sign Out

The information provided in this site is intended only for Healthcare Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Pte Ltd, Singapore is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.